Genetics, Neuronal Pathways, and Electrophysiology of Alzheimer’s Disease

  • Mohammad ZubairEmail author


Alzheimer disease is characterized as a brain disorder that impairs an individual’s ability of memorizing, thinking, and behavior. The condition is considered as the most common form of dementia, and it is likely to worsen over time; however, it is not a normal part of aging (Abraha et al. 2017). Dementia is associated with loss of memory and other cognitive capabilities of individuals. The individuals suffering from dementia have a comorbid health condition (Bunn et al. 2014). Forgetfulness is the major problem faced by the individuals suffering from Alzheimer, which affects their functionality at home and office. Dementia has been chosen as the most accurate term to describe Alzheimer’s disease (Mace and Rabins 2011). The individual remains confused, misplaces things, gets lost in familiar places, and is also troubled while communicating with peers. The onset of Alzheimer results in the prevention of brain cells to perform well. This condition may lead to disorientation, confusion, intellectual impairment, and memory loss (Bennett et al. 2005).


  1. Abraha I, Rimland JM, Trotta FM, Dell’Aquila G, Cruz-Jentoft A, Petrovic M, Cherubini A (2017) Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open 7(3):e012759CrossRefGoogle Scholar
  2. Alzheimer’s Association, 2005. Basics of Alzheimer’s diseaseGoogle Scholar
  3. Amjad H, Roth DL, Samus QM, Yasar S, Wolff JL (2016) Potentially unsafe activities and living conditions of older adults with dementia. J Am Geriatr Soc 64(6):1223–1232CrossRefGoogle Scholar
  4. Ashraf J, Ahmad J, Ali A, Ul-Haq Z (2018) Analyzing the behavior of neuronal pathways in Alzheimer’s using petri net modeling approach. Front Neuroinform 12:26CrossRefGoogle Scholar
  5. Austrom MG, Boustani M, LaMantia MA (2018) Ongoing medical management to maximize health and well-being for persons living with dementia. The Gerontologist 58(suppl_1):S48–S57CrossRefGoogle Scholar
  6. Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23(4):213–227CrossRefGoogle Scholar
  7. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005) Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64(5):834–841CrossRefGoogle Scholar
  8. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: back to the future. Neuron 68(2):270–281CrossRefGoogle Scholar
  9. Bunn F, Burn AM, Goodman C, Rait G, Norton S, Robinson L, Brayne C (2014) Comorbidity and dementia: a scoping review of the literature. BMC Med 12(1):192CrossRefGoogle Scholar
  10. Cacace R, Sleegers K, Van Broeckhoven C (2016) Molecular genetics of early-onset Alzheimer’s disease revisited. Alzheimers Dement 12(6):733–748CrossRefGoogle Scholar
  11. Castello MA, Soriano S (2014) On the origin of Alzheimer’s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev 13:10–12CrossRefGoogle Scholar
  12. De Strooper B, Karran E (2016) The cellular phase of Alzheimer’s disease. Cell 164(4):603–615CrossRefGoogle Scholar
  13. Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Weiner MW (2007) Different regional patterns of cortical thinning in Alzheimer’s disease and frontotemporal dementia. Brain 130(4):1159–1166CrossRefGoogle Scholar
  14. ElSharkawy AM (2014) Breast cancer. In: Al-Naggar RA (ed) Principles and practice of cancer prevention and control. OMICS Group eBooks, Foster CityGoogle Scholar
  15. Fazio S, Pace D, Kallmyer B, Pike J (2018) Alzheimer’s Association towards guidelines for dementia care practice: recommendations with emphasis on high-quality, person-centered care in long-term and community-based care settings. Alzheimers Dement 14:520–521CrossRefGoogle Scholar
  16. Gentier RJ, Verheijen BM, Zamboni M, Stroeken M, Hermes DJ, Küsters B, Van Leeuwen FW (2015) Localization of mutant ubiquitin in the brain of a transgenic mouse line with proteasomal inhibition and its validation at specific sites in Alzheimer’s disease. Front Neuroanat 9:26CrossRefGoogle Scholar
  17. Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, Zetterberg H (2014) Pathways to Alzheimer’s disease. J Intern Med 275(3):296–303CrossRefGoogle Scholar
  18. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16(6):358CrossRefGoogle Scholar
  19. Huang C, Wahlund LO, Dierks T, Julin P, Winblad B, Jelic V (2000) Discrimination of Alzheimer’s disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 111(11):1961–1967CrossRefGoogle Scholar
  20. Koppel J, Campagne F, Vingtdeux V, Dreses-Werringloer U, Ewers M, Rujescu D, Greenwald BS (2011) CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer’s disease. Mol Med 17(9–10):974CrossRefGoogle Scholar
  21. Loy CT, Schofield PR, Turner AM, Kwok JB (2014) Genetics of dementia. Lancet 383(9919):828–840CrossRefGoogle Scholar
  22. Mace NL, Rabins PV (2011) The 36-hour day: a family guide to caring for people who have Alzheimer disease, related dementias, and memory loss. JHU Press, BaltimoreGoogle Scholar
  23. Maslow K, Fortinsky RH (2018) Nonphysician care providers can help to increase detection of cognitive impairment and encourage diagnostic evaluation for dementia in community and residential care settings. The Gerontologist 58(suppl_1):S20–S31CrossRefGoogle Scholar
  24. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Primers 15(1):15056CrossRefGoogle Scholar
  25. National Institute on Aging. Alzheimer’s disease Fact Sheet. 2016. Available from:
  26. Poil SS, De Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen K (2013) Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI stage. Front Aging Neurosci 5:58CrossRefGoogle Scholar
  27. Putcha D, Brickhouse M, O’Keefe K, Sullivan C, Rentz D, Marshall G, Sperling R (2011) Hippocampal hyperactivation associated with cortical thinning in Alzheimer’s disease signature regions in non-demented elderly adults. J Neurosci 31(48):17680–17688CrossRefGoogle Scholar
  28. Quinodoz SA, Ollikainen N, Tabak B, Palla A, Schmidt JM, Detmar E, Aznauryan E (2017) Higher-order inter-chromosomal hubs shape 3-dimensional genome organization in the nucleus. bioRxiv.
  29. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63(11):1545–1550CrossRefGoogle Scholar
  30. Wang J, Zuo X, Dai Z, Xia M, Zhao Z, Zhao X, He Y (2013) Disrupted functional brain connectome in individuals at risk for Alzheimer’s disease. Biol Psychiatry 73(5):472–481CrossRefGoogle Scholar
  31. World Health Organization. WHO|Dementia. WHO [Internet]. World Health Organization. 2017. Available from:

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Medical Microbiology, Faculty of MedicineUniversity of TabukTabukKingdom of Saudi Arabia

Personalised recommendations